Venrock Healthcare Capital Partners III, L.P. - Feb 7, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
10%+ Owner
Signature
Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory
Stock symbol
KALV
Transactions as of
Feb 7, 2025
Transactions value $
$967,145
Form type
4
Date filed
2/11/2025, 07:51 PM
Previous filing
Feb 3, 2025
Next filing
Feb 27, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Purchase $684K +73.6K +1.47% $9.29 5.09M Feb 7, 2025 By Funds F1, F2, F3
transaction KALV Common Stock Purchase $37.8K +4.14K +0.08% $9.14 5.09M Feb 10, 2025 By Funds F3, F4, F5
transaction KALV Common Stock Purchase $245K +26.7K +0.52% $9.18 5.12M Feb 11, 2025 By Funds F3, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.15 to $9.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2 Consists of (i) 1,104,278 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,465 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,871,702 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
F3 VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
F4 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.11 to $9.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F5 Consists of (i) 1,104,993 shares held by VHCP3; (ii) 110,536 shares held by VHCP Co-3; and (iii) 3,875,053 shares held by VHCP EG.
F6 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.07 to $9.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F7 Consists of (i) 1,109,607 shares held by VHCP3; (ii) 110,998 shares held by VHCP Co-3; and (iii) 3,896,680 shares held by VHCP EG.